Study title: Phase II study of high-dose [131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paragangliomaJ Clin Oncol. 2009 Sep 1; 27(25):4162-8. Epub 2009 Jul 27
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: | |||||
Brands: | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: META-IODOBENZYLGUANIDINE | |||||
ATC code: | |||||
Document link: 2011-09 GE response 131 Meta-lodobenzylguanidine.doc | |||||
Document date: 2013-12-04 | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |